**Supplemental Table 7** Number of Injections and Clinic Visits During the Study Period for Eyes Treated with Intravitreal Bevacizumab Monotherapy Stratified by Presenting Visual Acuity Groups (Complete Case Analysis)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total** | **VA Worse Than 20/40**  **(Moderate to Severe Visual Impairment)** | **VA 20/40 and Better**  **(Mild Visual Impairment)** | **P Value** |
| **Month 12** |  |  |  |  |
| Number of eyes, n | 308 | 220 | 88 |  |
| Number of injections during 12 months interval, median (IQR) | 5 (3 to 8) | 5 (3 to 8) | 5 (3 to 6.5) | 0.085 |
| Number of visits during 12 months interval, median (IQR) | 10 (8 to 12) | 10 (7 to 12) | 10 (8 to 12) | 0.296 |
| **Month 24** |  |  |  |  |
| Number of eyes, n | 225 | 156 | 69 |  |
| Number of injections during 12 months interval, median (IQR) | 0 (0 to 3) | 1 (0 to 4) | 0 (0 to 3) | 0.107 |
| Number of visits during 12 months interval, median (IQR) | 6 (4 to 9) | 6 (4 to 9) | 5 (4 to 8) | 0.261 |
| **Month 36** |  |  |  |  |
| Number of eyes, n | 150 | 101 | 49 |  |
| Number of injections during 12 months interval, median (IQR) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 1) | 0.239 |
| Number of visits during 12 months interval, median (IQR) | 5 (3 to 7) | 5 (3 to 7) | 4 (3 to 7) | 0.737 |
| *VA = visual acuity, IQR = interquartile range* | | | | |